WPD Pharmaceuticals Inc. is primarily focused on the biotechnology sector, specifically in the field of oncology. The company is engaged in the research and development of medicinal products that utilize biological compounds and small molecules. This approach aims to create innovative therapies for cancer treatment, leveraging the unique properties of these compounds to target and combat various forms of cancer. The emphasis on both biological and small molecule research indicates a commitment to exploring diverse therapeutic avenues to enhance treatment efficacy and patient outcomes.

Despite the company's current lack of active business operations and the loss of control over its Polish subsidiary, WPD Pharmaceuticals retains a stake in the biotechnology research landscape through its shares in WPD Pharmaceuticals Sp. zo.o. This subsidiary is dedicated to advancing oncology research, which suggests that the company is still positioned to contribute to the development of new cancer therapies in the future. The focus on cutting-edge biotechnological advancements underscores WPD's potential to play a role in the evolving landscape of cancer treatment solutions.

Canada

WPD is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. WPD has 8 novel drug candidates with 4 that are in clinical development stage and 4 in pre-clinical development. These drug candidates were researched at institutions including MD Anderson Cancer Center, Mayo Clinic and Emory University, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.

WPD Pharmaceuticals

Company Details